Coldstream Capital Management Inc. Lowers Position in Moderna, Inc. (NASDAQ:MRNA)

Coldstream Capital Management Inc. lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNAFree Report) by 24.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,668 shares of the company’s stock after selling 867 shares during the period. Coldstream Capital Management Inc.’s holdings in Moderna were worth $265,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its position in Moderna by 7.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after buying an additional 187 shares in the last quarter. International Assets Investment Management LLC increased its position in Moderna by 6,528.9% during the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after buying an additional 381,808 shares in the last quarter. abrdn plc increased its position in Moderna by 477.5% during the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after buying an additional 399,843 shares in the last quarter. Van ECK Associates Corp increased its position in Moderna by 19.2% during the 4th quarter. Van ECK Associates Corp now owns 270,774 shares of the company’s stock valued at $26,929,000 after buying an additional 43,646 shares in the last quarter. Finally, Invesco Ltd. increased its position in Moderna by 19.8% during the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after buying an additional 517,683 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $157.57, for a total transaction of $2,363,550.00. Following the transaction, the director now directly owns 1,981,931 shares in the company, valued at $312,292,867.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $157.57, for a total value of $2,363,550.00. Following the transaction, the director now directly owns 1,981,931 shares in the company, valued at $312,292,867.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 647 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares in the company, valued at $406,651. The disclosure for this sale can be found here. Over the last three months, insiders have sold 185,209 shares of company stock worth $20,951,971. Corporate insiders own 15.20% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research analyst reports. William Blair reissued a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Canaccord Genuity Group lifted their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Thursday, May 2nd. Finally, Evercore ISI initiated coverage on Moderna in a report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 target price for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $126.46.

Check Out Our Latest Report on Moderna

Moderna Price Performance

NASDAQ MRNA opened at $166.61 on Monday. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $115.62 and its 200 day moving average is $100.78. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNAGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 earnings per share. Research analysts forecast that Moderna, Inc. will post -7.47 EPS for the current fiscal year.

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Articles

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.